



## CERTIFICATE OF ANALYSIS

Page 1 of 2

**Product Description:** V-PLEX® SARS-CoV-2 Panel 23 Kit  
**Kit Catalog Numbers:** K15567-Series; K15570-Series; K15568-Series; K15569-Series; K15571-Series; K15572-Series; K15573-Series  
**Kit Lot Number:** K0082030  
**Expiration Date:** 31 JUL 2023

### Kit Components: .

Description	Lot Number	Storage Temperature	Expiration Date
SARS-CoV-2 Plate 23	Z0057105	2-8°C	30 JUN 2024
Reference Standard 1	A0080286	≤ -70°C	28 FEB 2026
Serology Control 1.1	A00C0771	≤ -70°C	28 FEB 2026
Serology Control 1.2	A00C0772	≤ -70°C	28 FEB 2026
Serology Control 1.3	A00C0773	≤ -70°C	28 FEB 2026
SULFO-TAG™ Human ACE2 Protein	D0081708	2-8°C	31 JUL 2023
ACE2 Calibration Reagent 2	A0080327	2-8°C	31 OCT 2025
SULFO-TAG™ Anti-Human IgG Antibody	D00V0019	2-8°C	30 APR 2025
SULFO-TAG™ Anti-Human IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Human IgA Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgG Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgA Antibody	Not Kit Specific	2-8°C	See Label
Diluent 100	Not Kit Specific	2-8°C	See Label
MSD Blocker A Kit	Not Kit Specific	Room Temperature	See Label
MSD GOLD Read Buffer B	Not Kit Specific	Room Temperature	See Label

See product insert regarding which components are provided with each IgG, IgA, IgM, or ACE2 kit.

### Plate Uniformity Testing Results:

Parameter	Precision			Uniformity	Signal
	CV of Intra-plate Averages	Average Intra-plate CV	Max Intra-plate CV	Average Uniformity Metric	Average Signal
SARS-CoV-2 Spike	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.529; BA.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (AY.4.2)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (P.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.7)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.351)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000



## CERTIFICATE OF ANALYSIS

Page 2 of 2

### Coating Confirmation Testing Results:

Spot	Description	Result
1	SARS-CoV-2 Spike	Pass
2	SARS-CoV-2 Spike (B.1.1.529; BA.1)	Pass
3	SARS-CoV-2 Spike (AY.4.2)	Pass
4	SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	Pass
7	SARS-CoV-2 Spike (P.1)	Pass
8	SARS-CoV-2 Spike (B.1.1.7)	Pass
9	SARS-CoV-2 Spike (B.1.351)	Pass
10	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	Pass

Note: Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as “Alt Seq#.”

### Functional Testing Results:

Sample Type	Calibrator	Controls		Samples	
Metric	Avg Signal Ratio Test:Reference	Control Recovery	Control Conc. CV	Avg % Difference Test:Reference	Slope Test:Reference
SARS-CoV-2 Spike	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.1.529; BA.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (AY.4.2)	50 – 200%	>130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.617.2; AY.4) <b>Alt Seq 2</b>	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (P.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.1.7)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.351)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2

### Additional Comments:

Functional testing was executed using SARS-CoV-2 Plate 23 (Z0057105), SULFO-TAG Anti-Human IgG Antibody (D00V0019), Reference Standard 1 (A0080286), and Serology Controls (A00C0771, A00C0772, A00C0773).

All kit components were manufactured and tested according to MSD documents. The lots listed in the Kit Components table meet MSD’s specifications.

### Statement:

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
<b>Review/Approval</b>	Karen Hamilla	Quality		09 JUN 2022